Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 14, 2007

NIAID Contracts SRI International for $15.5M to Further HIV and AIDS Therapeutic Research

  • SRI International was awarded $15.5 million to provide preclinical services to NIAID to support development of drugs and vaccines for HIV and AIDS. 

    Under the terms of this agreement, SRI will provide toxicology, pharmacology, pharmacokinetics, toxicogenomics, and other services. The collaborators believe that this will ultimately help the NIAID with IND applications.

    This is an adjunct to a preexisting NIAID contract held by SRI since 1991. Under the terms of the original agreement, SRI has been providing preclinical services for the past 16 years, for more than 200 drugs and vaccines at various stages of development.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »